Vivex Announces New Peer-Reviewed Publication Demonstrating Long-Term Fusion Outcomes with VIA Form+™ in Lumbar Interbody Fusion

Vivex Biologics, Inc., a leading medical technology company developing and delivering innovative allografts for ...
abc27

Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration

MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced that it has completed subject enrollment in its ASCEND ...
WIVB-TV

Data readout expected in Q1 2026

MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company has enrolled 50% of the patients in its ASCEND ...
Business Insider

Vivex Biologics Treats First Patient in its Restore Trial Evaluating VIA Disc NP™ for Patients with Degenerative Disc Disease

MIAMI, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced that it has treated the first patient in its Restore U.S.